Morganka / Shutterstock.com
In the competitive world of cancer treatment it’s becoming ever more important to stand out from the crowd. LSIPR speaks to TapImmune’s chief executive Glynn Wilson on why he thinks the company does.
In just five years Glynn Wilson, chief executive of TapImmune, estimates the Seattle-based company will be worth more than a $1 billion. It’s a big claim to make for a company that currently is not making money but Wilson sees no reason why it can’t aim for the top.
The company’s primary function is treating cancer and infectious disease through immunotherapy. Rather than using traditional chemotherapy techniques, which seek to kill cancerous cells, TapImmune’s philosophy centres on boosting the body’s immune system to fight disease.
“The real problem we are trying to solve is finding a way to stimulate the body’s cellular immune system to kill cancer cells and virally infected cells,” Wilson tells LSIPR.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
cancer treatment; patents; patent applications; TapImmune